Evidence / D'Anna et al. · 2009
Hot flushes through two years in a genistein trial
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Vasomotor subgroup analysis of a randomized, double-blind, placebo-controlled parent trial.
- Product relevance
- Ingredient research involving genistein.
- Sample or population
- 389 randomized in the parent trial. This analysis included 236 participants with hot flushes (119 genistein, 117 placebo).
- Studied dose
- 54 mg/day of genistein or placebo.
- Duration
- 24 months.
- Finding
- Hot-flush frequency fell more with genistein at 12 months. There was no further decrease in either group by 24 months. The groups did not differ significantly in mean endometrial thickness or the vaginal maturation score.
- Limitations
- The analysis came from a symptomatic subgroup of the same parent cohort. It extends the earlier one-year report rather than adding an independent trial.
- Study quality
- The outcomes, study design and limitations were reviewed. No formal risk-of-bias rating was assigned for this summary.
- Funding and disclosures
- Funding and conflicts for this publication were not verified from the PubMed abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.
Licensed product information
S-EQUOL PLUS · NPN 80143622
May reduce severe and frequent menopausal symptoms (such as hot flashes and/or night sweats).